COVID-19-induced transaminitis and hyperbilirubinemia: Presentation and outcomes.
World J Gastroenterol
; 29(7): 1123-1130, 2023 Feb 21.
Article
in English
| MEDLINE | ID: covidwho-2279325
ABSTRACT
The risk of liver injury in patients with coronavirus disease 2019 (COVID-19) infection is quite evident. Furthermore, liver function test abnormalities are still detected in COVID-19 patients despite the development of antivirals and the availability of several types of vaccines. This editorial describes liver involvement during COVID-19 infection in patients with or without preexisting liver injury, such as chronic liver disease, to elucidate COVID-19-induced liver function abnormalities and their severity, pathophysiology, clinical manifestations, and clinical and laboratory outcomes. We also discuss the effect of vaccination against COVID-19 to better understand host factors, such as age, gender, and race, on the incidence and severity of liver dysfunction at initial presentation and during the illness. Finally, we summarize the results of relevant meta-analyses published to date and highlight the importance of adequate liver function monitoring in the current climate of the overwhelming COVID-19 pandemic.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Liver Diseases
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
/
Reviews
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Language:
English
Journal:
World J Gastroenterol
Journal subject:
Gastroenterology
Year:
2023
Document Type:
Article
Affiliation country:
Wjg.v29.i7.1123
Similar
MEDLINE
...
LILACS
LIS